Why the study?
Aortic dissection requires immediate diagnosis and treatment, but current diagnostic techniques present substantial obstacles to early detection.
Do serum biomarkers improve early diagnosis and prognostic assessment in patients with aortic dissection?
Do serum biomarkers improve early diagnosis and prognostic assessment in patients with aortic dissection?
Serum biomarkers such as D-dimer, matrix metalloproteinases, and smooth muscle myosin heavy chain show promise in facilitating prompt diagnosis and risk assessment of aortic dissection.
Answers are grounded in this paper and cite their sources.
May aid early aortic dissection differentiation; hypothesis-generating and requires prospective validation before clinical adoption.
Aortic dissection (AD) is a potentially fatal cardiovascular issue that needs to be diagnosed and treated very away. Although early detection is essential for bettering patient outcomes, there are substantial obstacles with the diagnostic techniques used today. Promising pathways for improving AD prognosis evaluation and early detection are presented by recent developments in serum biomarkers. The most recent research on serum biomarkers for AD is reviewed here, with an emphasis on the prognostic and diagnostic utility of these indicators. A number of biomarkers, including as matrix metalloproteinases, soluble elastin fragments, smooth muscle myosin heavy chain, and D-dimer, have been identified as putative markers of AD. These indicators are indicative of multiple pathophysiological mechanisms associated with AD, including inflammation, extracellular matrix remodeling, and vascular damage. Research has indicated that they are useful in differentiating AD from other acute cardiovascular diseases, facilitating prompt diagnosis and risk assessment.
No takes yet. Share an insight, caveat, or question.
Muzammil et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: